TLDR
- Repligen is buying BioLife Solutions in a cash-and-stock deal worth ~$1.5 billion
- BioLife holders get $11.25 cash plus 0.1442 RGEN stock per share â a 6.2% premium to last close, valuing it at $31 per share
- The deal is expected to add at least $0.05 EPS in year one and $0.25 in year two
- Repligen expects at least $20 million in synergies in year one, rising to $30 million in year two
- Deal is expected to close in Q4 2026, pending regulatory and shareholder approvals
Repligen (RGEN) fell roughly 5.84% on Wednesday after announcing it would acquire BioLife Solutions (BLFS) in a deal worth approximately $1.5 billion.
The deal is structured as 64% Repligen stock and 36% cash. BioLife holders will receive $11.25 per share in cash and 0.1442 RGEN shares for each share they own. That puts the total value at $31 per share â a 6.2% premium to BioLife’s last closing price.
Both boards have unanimously approved the transaction. It is expected to close in the fourth quarter of 2026, subject to shareholder and regulatory sign-offs.
M&A: Repligen $RGEN will acquire BioLife Solutions $BLFS for about $1.5 billion, valuing the company at $31 per share in cash and stock. The deal is expected to close in Q4 2026 and become accretive to adjusted EPS in the first year. pic.twitter.com/FSIkQLEIpQ
— Wall St Engine (@wallstengine) July 22, 2026
Repligen said the deal will be accretive to adjusted earnings per share by at least $0.05 in year one and at least $0.25 in year two. The company plans to fund the cash portion using cash on hand and expects to maintain more than $300 million in pro forma cash after closing.
The company projects at least $20 million in cost synergies in the first year following close, rising to at least $30 million in year two. Those savings are expected to come from cutting public-company overhead, G&A efficiencies, and supply-chain optimization.
What Repligen Is Getting
BioLife’s core product is its biopreservation media platform, led by CryoStor. That product line supports 18 commercially approved therapies and is used in the majority of U.S. commercially sponsored cell-based therapy trials.
BioLife also brings a portfolio of cell-processing tools and a high-margin consumables business with recurring revenue. Repligen said the combination will help it serve cell therapy customers more broadly, including expanded reach in Asia Pacific.
BioLife had already been streamlining before the deal. In October 2025, it sold its evo cold-chain logistics unit for $25.5 million, sharpening its focus on cell and gene therapy tools.
Recent Revenue Performance
Repligen reported preliminary Q2 2026 revenue growth of approximately 12% to 13% on an organic basis. BioLife’s preliminary Q2 revenue grew approximately 21% year-over-year.
The deal follows Danaher’s comments on Tuesday pointing to a recovery in bioprocessing demand, as biotech and pharma companies increase spending after a period of slower research activity and inventory drawdowns.
It also comes about a month after German drugmaker Merck KGaA announced an $11.3 billion deal to acquire Bio-Techne, another tools company serving drug development.
Repligen CEO Olivier Loeillot said BioLife’s portfolio is “highly differentiated” and that the acquisition builds on its existing cell therapy footprint. BioLife CEO Roderick de Greef called Repligen an “ideal partner” given its global commercial reach and complementary technologies.
RGEN was down 5.84% and BLFS was up 0.34% in early Wednesday trading.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions â all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
